Compare MAR & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MAR | SNY |
|---|---|---|
| Founded | 1927 | 1994 |
| Country | United States | France |
| Employees | N/A | 74846 |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 97.7B | 104.5B |
| IPO Year | 2005 | N/A |
| Metric | MAR | SNY |
|---|---|---|
| Price | $363.50 | $43.93 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 16 | 5 |
| Target Price | ★ $359.31 | $58.00 |
| AVG Volume (30 Days) | 1.5M | ★ 4.2M |
| Earning Date | 05-06-2026 | 04-23-2026 |
| Dividend Yield | 0.76% | ★ 3.47% |
| EPS Growth | ★ 14.17 | N/A |
| EPS | ★ 2.43 | N/A |
| Revenue | ★ $26,186,000,000.00 | N/A |
| Revenue This Year | $304.38 | $3.49 |
| Revenue Next Year | $5.38 | $6.10 |
| P/E Ratio | $154.84 | ★ $6.14 |
| Revenue Growth | ★ 4.33 | N/A |
| 52 Week Low | $253.76 | $40.89 |
| 52 Week High | $410.98 | $52.68 |
| Indicator | MAR | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 38.58 | 54.42 |
| Support Level | $345.82 | $43.32 |
| Resistance Level | $367.50 | $45.18 |
| Average True Range (ATR) | 8.54 | 0.76 |
| MACD | -2.13 | 0.22 |
| Stochastic Oscillator | 1.15 | 93.18 |
Marriott operates 1.8 million rooms across roughly 30 brands. At the end of 2025, luxury represented roughly 10% of total rooms, premium was 42%, select service was 46%, and midscale was 2%. Marriott, Courtyard, and Sheraton are the largest brands, while Autograph, Tribute, Moxy, Aloft, and Element are newer lifestyle brands. Managed and franchised represented 99% of total rooms as of Dec. 31, 2025. North America makes up 61% of total rooms. Managed, franchise, and incentive fees represent the vast majority of revenue and profitability for the company.
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.